{"ticker": {"uuid": "99fbd222-96bd-4eb1-a26c-9af2e81f99eb", "symbol": "OCS", "name": "Oculis Holding AG Ordinary shares", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Oculis Holding AG (OCS) Investigation: Bronstein, Gewirtz & Gross", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Oculis Holding AG (NASDAQ: OCS) on behalf of investors. This investigation follows a significant stock price drop after Oculis announced the failure of its lead candidate, OCS-01, in two late-stage trial", "url": "https://natlawreview.com/press-releases/oculis-holding-ag-ocs-investigation-bronstein-gewirtz-grossman-llc-2", "source_name": "The National Law Review", "published_at": "2026-07-15T09:12:45", "published_display": "15 Jul 2026 09:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Oculis Holding AG \u2013 NASDAQ:OCSAW", "summary": "This article focuses on the enterprise value to revenue forward metric for Oculis Holding AG, traded on NASDAQ under the symbol OCSAW. It appears to be a financial data snippet from TradingView, providing an overview of the company's financial information within that platform. Th", "url": "https://www.tradingview.com/symbols/NASDAQ-OCSAW/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T19:10:41", "published_display": "13 Jul 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Enterprise value to EBITDA forward of Oculis Holding AG \u2013 NASDAQ:OCSAW", "summary": "This article provides financial data for Oculis Holding AG (NASDAQ: OCSAW), specifically focusing on its Enterprise Value to EBITDA forward metric. The content highlights that the market was closed at the time of publication, with no trades observed. It appears to be a stub or da", "url": "https://www.tradingview.com/symbols/NASDAQ-OCSAW/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T09:41:16", "published_display": "13 Jul 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Technical Reactions to OCS Trends in Macro Strategies", "summary": "This article provides a technical analysis of Oculis Holding Ag (NYSE: OCS), highlighting weak near-term sentiment but strong mid and long-term support signals. It outlines institutional trading strategies including position trading, momentum breakout, and risk hedging, along wit", "url": "https://news.stocktradersdaily.com/news_release/101/Technical_Reactions_to_OCS_Trends_in_Macro_Strategies_071126070602_1783811162.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-11T19:06:00", "published_display": "11 Jul 2026 19:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities", "summary": "Oculis Holding AG announced the publication of notifications regarding transactions by persons discharging managerial responsibilities. Specifically, the notification concerns the vesting and settlement of Restricted Stock Units (RSUs) previously granted to a company director, Ri", "url": "https://uk.finance.yahoo.com/news/oculis-publishes-notifications-transactions-persons-200500440.html", "source_name": "Market source", "published_at": "2026-07-08T20:05:03", "published_display": "08 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Oculis Holding AG \u2013 SWB:CR5", "summary": "This page from TradingView provides financial information for Oculis Holding AG (SWB:CR5), specifically focusing on its price to book forward metric. The content highlights the company's financials, news, and community forecasts, and mentions that the market was closed with no tr", "url": "https://www.tradingview.com/symbols/SWB-CR5/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T02:10:45", "published_display": "08 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Oculis Holding AG \u2013 NASDAQ:OCS", "summary": "This article provides financial information for Oculis Holding AG (NASDAQ: OCS), specifically focusing on its forward price-to-earnings ratio. It presents a data table indicating the period, value, change, and percentage change for this metric, noting that the data is sourced fro", "url": "https://www.tradingview.com/symbols/NASDAQ-OCS/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T01:10:45", "published_display": "08 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Oculis Holding AG \u2013 SWB:CR5", "summary": "This article provides financial data for Oculis Holding AG (SWB:CR5) focusing on its enterprise value to revenue forward metric. The content indicates the stock is traded on the Stuttgart Stock Exchange and presents an overview of its financials within the TradingView platform. T", "url": "https://www.tradingview.com/symbols/SWB-CR5/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T14:09:53", "published_display": "07 Jul 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference", "summary": "Oculis Holding AG announced its participation in the Piper Sandler Virtual Ophthalmology Conference, where its management will discuss its late-stage pipeline. Key programs include Privosegtor for optic neuropathies, which has received Breakthrough Therapy and PRIME designations,", "url": "https://www.globenewswire.com/news-release/2026/07/02/3321128/0/en/oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-conference.html", "source_name": "GlobeNewswire", "published_at": "2026-07-06T20:41:16", "published_display": "06 Jul 2026 20:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis Holding AG Warrants 2023-06.03.28 on OCULIS HOLDING Financial Disclosures & SEC Filings", "summary": "This page provides access to financial disclosures and SEC filings for Oculis Holding AG (OCSAW). It lists various documents including earnings reports, annual reports, event transcripts from conferences, and significant press releases, spanning from 2025 to 2026. The disclosures", "url": "https://www.tradingview.com/symbols/NASDAQ-OCSAW/documents/", "source_name": "TradingView", "published_at": "2026-07-06T05:42:08", "published_display": "06 Jul 2026 05:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis to present updates on late-stage eye disease treatments at Piper Sandler conference", "summary": "Oculis Holding AG announced its participation in the Piper Sandler Virtual Ophthalmology Conference on July 10, 2026. The company will discuss its advanced portfolio of eye disease treatments, including Privosegtor and Licaminlimab. Oculis aims to achieve significant milestones i", "url": "https://pluang.com/en/news-feed/oculis-ikut-konferensi-virtual-piper-sandler-ophthalmology", "source_name": "Pluang", "published_at": "2026-07-02T08:40:46", "published_display": "02 Jul 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis to Participate in Piper Sandler Virtual Ophthalmology Conference Fireside Chat", "summary": "Oculis Holding AG will participate in a fireside chat at the Piper Sandler Virtual Ophthalmology Conference on July 10, 2026. The company will discuss its late-stage product pipeline, including Privosegtor, which has Breakthrough Therapy designation for optic neuritis, and Licami", "url": "https://www.quiverquant.com/news/Oculis+to+Participate+in+Piper+Sandler+Virtual+Ophthalmology+Conference+Fireside+Chat", "source_name": "Quiver Quantitative", "published_at": "2026-07-02T08:10:00", "published_display": "02 Jul 2026 08:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis to Present Late-Stage Pipeline Update at Piper Sandler Virtual Ophthalmology Conference", "summary": "Oculis Holding AG, a biopharmaceutical company, announced it will present a late-stage pipeline update at the Piper Sandler Virtual Ophthalmology Conference on July 10, 2026. The presentation will highlight Privosegtor, a neuroprotective candidate with Breakthrough Therapy design", "url": "https://www.quiverquant.com/news/Oculis+to+Present+Late-Stage+Pipeline+Update+at+Piper+Sandler+Virtual+Ophthalmology+Conference", "source_name": "Quiver Quantitative", "published_at": "2026-07-02T07:40:46", "published_display": "02 Jul 2026 07:40", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis spotlights late-stage eye drugs at Piper Sandler event", "summary": "Oculis (Nasdaq: OCS) is scheduled to participate in the Piper Sandler Virtual Ophthalmology Conference on July 10, 2026, where its management will discuss late-stage programs. These include Privosegtor, which has FDA Breakthrough Therapy and EMA PRIME designations for optic neuri", "url": "https://www.stocktitan.net/news/OCS/oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-ciy984j33vsr.html", "source_name": "Stock Titan", "published_at": "2026-07-02T07:40:46", "published_display": "02 Jul 2026 07:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trading the Move, Not the Narrative: (OCS) Edition", "summary": "This article provides an AI-driven analysis for Oculis Holding Ag (NYSE: OCS), highlighting strong sentiment across all horizons for an overweight bias despite elevated downside risk due to a lack of additional long-term support. It details three institutional trading strategies\u2014", "url": "https://news.stocktradersdaily.com/news_release/134/Trading_the_Move,_Not_the_Narrative:_OCS_Edition_063026055802_1782856682.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-30T17:58:00", "published_display": "30 Jun 2026 17:58", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis Holding AG Actuals & Estimates (NASDAQ:OCS)", "summary": "This article provides an overview of Oculis Holding AG (NASDAQ: OCS) stock, including its current price, market capitalization, and analyst forecasts. It details financial actuals and estimates for the income statement, balance sheet, and cash flow, along with frequently asked qu", "url": "https://www.tradingview.com/symbols/NASDAQ-OCS/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T02:09:37", "published_display": "26 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis (NASDAQ: OCS) details late-stage eye drugs and cash runway into 2029", "summary": "Oculis Holding AG (NASDAQ: OCS) has provided an updated corporate presentation detailing its late-stage ophthalmic and neuro-ophthalmic drug pipeline and a strong financial position, projecting a cash runway into the second half of 2029, excluding a CHF100 million loan facility. ", "url": "https://www.stocktitan.net/sec-filings/OCS/6-k-oculis-holding-ag-current-report-foreign-issuer-54e0573b556d.html", "source_name": "Stock Titan", "published_at": "2026-06-25T19:40:23", "published_display": "25 Jun 2026 19:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OCS Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "Oculis Holding AG (OCS) has a current stock price of $11.74, showing a 1.56% increase in the last 24 hours. Analysts provide a wide forecast range for OCS, with a maximum estimate of $51.93 and a minimum of $22.67. The company's stock has experienced significant volatility, inclu", "url": "https://www.tradingview.com/symbols/NASDAQ-OCS/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T17:40:23", "published_display": "25 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS", "summary": "Pomerantz LLP is investigating claims on behalf of investors of Oculis Holding AG (NASDAQ: OCS) due to potential securities fraud or unlawful business practices. This investigation stems from Oculis's announcement on May 29, 2026, that two late-stage trials for its lead candidate", "url": "https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-oculis-holding-ag---ocs-302808841.html", "source_name": "PR Newswire", "published_at": "2026-06-25T15:09:50", "published_display": "25 Jun 2026 15:09", "sentiment": "negative", "sentiment_pct": 28, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OCS - Oculis Holding AG Revenue Breakdown", "summary": "This article provides a detailed financial breakdown of Oculis Holding AG (OCS), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators, insider/institutional ownership, and analyst recommenda", "url": "https://finviz.com/stock?t=OCS&b=2&p=m&ty=rv", "source_name": "Finviz", "published_at": "2026-06-24T16:12:22", "published_display": "24 Jun 2026 16:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(OCS) Volatility Zones as Tactical Triggers", "summary": "This article from Stock Traders Daily discusses Oculis Holding Ag (NYSE: OCS), providing a detailed analysis based on AI-generated signals. It identifies a positive near-term sentiment within a long-term strength context, despite mid-term weakness and elevated downside risk. The ", "url": "https://news.stocktradersdaily.com/news_release/139/OCS_Volatility_Zones_as_Tactical_Triggers_061926044602_1781901962.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-19T17:09:45", "published_display": "19 Jun 2026 17:09", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm", "summary": "The Schall Law Firm is investigating Oculis Holding AG (NASDAQ: OCS) for potential securities law violations after the company announced its Phase 3 DIAMOND trials failed to meet primary endpoints, leading to a decision against pursuing FDA filing for its drug candidate. Investor", "url": "https://www.globenewswire.com/news-release/2026/06/17/3313555/0/en/ocs-investors-have-opportunity-to-join-oculis-holding-ag-fraud-investigation-with-the-schall-law-firm.html", "source_name": "GlobeNewswire", "published_at": "2026-06-17T14:10:33", "published_display": "17 Jun 2026 14:10", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Oculis Holding AG (OCS) And Encourages Shareholders to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating Oculis Holding AG (OCS) following the failure of its lead candidate, OCS-01, in two late-stage trials for diabetic macular edema. This news led to a significant drop in Oculis's stock price. The firm is encouraging affected shar", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-is-investigating-oculis-holdi-1172660", "source_name": "ACCESS Newswire", "published_at": "2026-06-17T10:39:10", "published_display": "17 Jun 2026 10:39", "sentiment": "negative", "sentiment_pct": 20, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis executive Sylvia Cheung reports June 10 share purchase", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNWWUxbXZIRFVLS1MyZUxpak9JMmVRTkpENEZmUm1tV0ltVXBoY011RE9adnZlWWliQzctdGVPanpxeG1xclVSZ2xwZG1qZWFUb25UUEFCZDVRXzRPaTFSV0Iwcks1WUczMWNoYXQxZ25yanJRalFSNmhMUTdQYnlFVFQ4RlVzM2VWYlRSWnZoN1ZVR1h1c19uZmU1Y1NzR1RSS0ZXOV9FeFotMjFPTGwtcg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/oculis-present-privosegtor-upcoming-clinical-080000630.html", "source_name": "GlobeNewswire", "published_at": "2026-06-11T08:00:00+00:00", "published_display": "11 Jun 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/oculis-announces-first-patient-randomized-080000550.html", "source_name": "GlobeNewswire", "published_at": "2026-06-09T08:00:00+00:00", "published_display": "09 Jun 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis executive and board member buys more company shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPMmtHYm5CbkRFYWdPV1h1UENJQ2ZnYUpaem5ubDNFbW1SZFpTaXI4UC1ORHV2UkNhaUViSDA4czhOTm9JZjhISGdBVUgxQ3hzRUJ6Si1jN09uc3JpbUdyR1ZXRERKcmdXTm9IclB0MmFSQzlrZHNYZ1B1cTVmVVpDWFoxc2w1WjNma0dEX2tfTGpOcXJ3alBocEdFTk15dTcwby1VRnNnN2tzMUljVHM2aA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/oculis-present-47th-annual-goldman-192500295.html", "source_name": "GlobeNewswire", "published_at": "2026-06-08T19:25:00+00:00", "published_display": "08 Jun 2026 19:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles", "summary": "", "url": "https://finance.yahoo.com/m/d56fa666-fe35-3c9c-a633-59b92a9d0d77/nan-fung-group-sells-%244.3.html", "source_name": "Motley Fool", "published_at": "2026-06-08T11:16:03+00:00", "published_display": "08 Jun 2026 11:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eye drug maker Oculis to outline $7B+ optic neuritis market plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOZDZwYWF1c2l0YTVCNEc4UklaMTFlS3pMb0UtclQxYzVMQzdydlNxcVpnZGxFRmw2NW5lc3htaVBqRlU2OHluWWt6b1dKOC1aN3RYanIzNmNUV3BlaGJMcWphRXFLUDZqOHVhdGF1OHRGdnZzWTJBdWl1M29VWGZBZF8zbE40Q21jY2hPVFRvVTc2TTFseFY5dmFQRENMM194S0pFenVFSlhPN2xDak1fS1lfb0FrYXlqSFFrYkhMcw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis Holding AG (OCS) Securities Fraud Investigation - Levi & Korsinsky", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxOUGtwdWtFdkRaN1VvcFFkNzI0THhxdEtqckd4cjBjVHBnUGQzcHVZVlY2dlBweU0yaWpjeGUtVVFuVUF3bVpia3V1MmhWS0U3UVNVVDdUaUo0VjQzYUJSTTg3YkkyTkhOTF92RHBtb0xnd2pqNVcwN0VIRWsyZndpaEZsNldHV2ZJNEUtY3FiU3pJbV8wXzBjS0NfY09lUi1Qc2xybmkwM2NZeVNoRDQwZUsxeVlUVkdrS3JSSC1DRkxlUGFXXzFJ?oc=5", "source_name": "Morningstar", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lost Money on Oculis Holding AG (OCS)? Contact Levi & Korsinsky About Investigation", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPUld2dkhwQVg4WTQzV0t6MUcxZGc2TmVvTWdwTVBvaWQ0RnVwaVhMTGw1b3E1YlpMMFVlMmlFOGhwXzlmR1dVQVN3VkFXVEVjNjJkLVRMczBUZlpUaFpyWWQ1WWwtNGdqemEzQUFXTWVYTnR0eXdwNFgzSHd6R3dtUUJnYWV3VGdXVGoxYkM4aURiZlkwWU1OaUV4aE5uZXRuSTNDYWZqYkl5RVFodXRaX1lWRzdjbGZ6dENiMml4OA?oc=5", "source_name": "TMX Newsfile", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis Holding (OCS) Is Down 60.1% After OCS-01 Trial Failure And Pipeline Pivot \u2013 Has The Bull Case Changed?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxOcUxYM0NxUUJmWWNucWlhQXk2ZU50dFFnWG9ESHAtbDlFcEM5R3I1ZnNSeXVsUjlWaDYzN1RGWFNPQzdqZ1JnN2J5SXZMUjY2enRKT29OcVZHRTRfMkJ6Y2lBODg2MkZSVTc1RzM4S3ZpYk84OUJtSkxzQ0prZnhCaDYzNzdacmFzU1NNbk4wMElwd1NMR0g1Q1pPbnBfY3hwY0lfaF9sSkpYNmduRnVQcE9sNzh2UHBfeGt5TmpVMjYxMVVCYWxGZTA2bnNINUNwTFJOMXJTNHlCUmFiMlV1WNIB5gFBVV95cUxPbEJwREZybUhIcWg1YTc0b3AyX2J2OUJZWGFWbUJUbHpWS3h4OV9Nd3otU1BZM2xZTHJhQmVoQ0JBWkhNYmZXc01kVHNFRWRlRHp0NjF2NXdib3NfVVhpa3k3V2U1Z1REWUdxV25Vam9oUTdwdWg5cnJoUVljcDVnbUJNcHlkZmVHRVVaUDJhaGpya1ZwSTZITnkxYXRVQ2ZNbWlNQzJJRGxXWWdLMmFGRlJXYXc1UWFSVGZtanZHN010b1dRQW5MdkFJcW14NUtIR1dBdzlsRnBPNkxnUlYyT1pKeVQxQQ?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OCS Stock Price and Chart \u2014 NASDAQ:OCS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTE5EZ1h6UmxTWEhMX19IMXlHcE1fN1BFSm81cncwR25HMnVodExBenhHbjNObkR0bHROQlRyZDNJalNLeDVLZWE3N1dJOGFaeEFrbjZWVlduXzFkNzQ?oc=5", "source_name": "TradingView", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Levi & Korsinsky Announces Investigation of Securities Claims Against Oculis Holding AG (OCS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxQV3dkTU1zM0ktNEpOVDl6LWFjcUc2Tnp2VXhpa2VodkxFeDR1RHM0emlxRW5VRm9HQUVMUnpDMEZFMW9UY0Utall1cXZfTlgzTGY5SmNuLTNaYnNOaG1neFRpYnlJOXNPXzRkUm1WUHg2RXgtQ0NfWmxjeUt2Q0NPTWJjN21IVDhpYlF3N3QyS2Jib3M5ZmIydXpUb29tU2FHSjRMb3hxMF9FamNKRktJeWVxcmNmbGpTVklVTkMweWNVUW55LWdfVnE2MWJzMTY5WlBVWm90alo1T0tUVzh6blRjY3pqOE5mSS12NGdiYmhyVWdORVFv?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OCS Investor Alert: Levi & Korsinsky Investigates Oculis Holding AG (OCS) for Potential Securities Fraud", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxQOVR6T3hPbGJNWlBGOFVHc0RKbXcwcEk4TGtjT09iUEY4TnROWkhIWUktUllxaS1iZzZhZTNpck1vMTVvaVpQY3p0VExmeU5JZDdSM3RXbnhTMnpHWGZvaXEyWWJUMlctM3VfYjh0bmlKcWc0SXdJS0RqbDdzTGh1RjBtM0NBZWVKeGM2RzlFazJfNXlLUTRiQ21rV2RpT2tuT1o2TFI1UjV0blVJQ0JiNENyeWFZa2xVSThJY3hZeUhKWmdyZThnaHhSMVpOa2xEVkRTSGNqX1dWcXV1S2hQTlRKcWEtc3FFVzFjYQ?oc=5", "source_name": "Business Wire", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis Resets After OCS-01 Setback And Refocuses On Late-Stage Pipeline", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Fair Value analysis helped investors avoid a 42% loss in Oculis By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPRm5ua0JKQWRzV2gwOVlPcm9sdGF5NHRmb2NWTmhVNDh0RXJDTnozZjZPdGliZWdaZlZuWlRPczlOTWJkd2wyLTBnczM2emlsMkMzUmhPSHFHYWZaZHpoY0xkYWRnZGtrU1ZUbjIyc3FZaHVQdWRHR2JxamFhWng1dnh6RHRuU0JjYzdFSFAyM0xxM3J3Mkc4X3FqeEdnS0R3b3NfVFVQaHlqU2Vpam5XcmJ5LVdtNlZ6UnlxNXJJbUZGSGlLQkE?oc=5", "source_name": "Investing.com", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis Holding AG Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Oculis Holding AG (OCS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigJBVV95cUxQYURKUUR4X3B2bDdMeGdUM2RHRXk2YjVHTmcxTDBXT1A0TGlUUGFLckNhR29XbUVlajFjN3oyMThiZzBBcWlZMmJuZllCeXlSNWp5WlotV1FpYlg1ZDJyclBIZXJDU0NXVVZZMEtzMmZNTUtNbGhsUm93SUl6NXkwWjFpcjVRMHhsV3N5czJGNXNTeURjTmwzXzdKWnVtQS11ek1IcmowT2Jtd0RFWU5wSEFmcTNmUzF3NEl0MldnNExfamNtWWtjSkNVSl9RQ1A3dnkxVlFCZlVaZ2pXVjRxamtNbGM5Z1NjdTR2cTJ4Z1BnREgyNGtvN0VweGljVnFfTGVNSWU4M1RIQQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis Shelves FDA Filing After Phase 3 DME Trials Miss Key Vision Goals", "summary": "", "url": "https://finance.yahoo.com/m/8c0e74c5-50f6-333d-b4df-f3ab03dec3a6/oculis-shelves-fda-filing.html", "source_name": "MarketBeat", "published_at": "2026-05-31T21:03:56+00:00", "published_display": "31 May 2026 21:03", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis Holding AG Phase 3 Trial of Potential Eye Drops for Diabetic Patients Fails to Primary Endpoint", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/oculis-holding-ag-phase-3-194641190.html", "source_name": "MT Newswires", "published_at": "2026-05-29T19:46:41+00:00", "published_display": "29 May 2026 19:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis Announces Phase 3 Trial Results for OCS-01 Eye Drops in Diabetic Macular Edema, Shifts Focus to Other Development Programs", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxPc1JkRDhQdE0xVi10LV85VjBRRnFodndtc05aQXQ3clRvVUxmTk5uRGhzcjctYUl3V2ptVldyaE83RVVVR3hRVWxyY2o2NXF2Mmw3SkF4R0ZNTExPaFYzeTJ2cTZOeHM3SDJLU3dzRjlFR2RyWWtSS01GVi13V1dKcTEwdFlqd2cwS0ViSzc0dE8zRW11NTlRRVh6N2h4R0RUaVo5UUdpdVRQOVpscnBtRnFSaXRqck1NbzNIMFJmVTdVMlBtLVN1QS00cHJIRWxPTGtCT0RORUFQdnRhMUxOZ2VtLTlkdWliTl9ON1U5WHYzX0FVSEM4?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Weighing Oculis Holding (NasdaqGM:OCS) Rich P/B Against DCF Upside After Strong Multi Year Share Gains", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOUlF3eVNTMl9qRV9lZDdnb21PeDVYRWJJNF9jM056RTBicGIzcEE1OU54RWk5cm9EMmR0OGNIY1A2UHB5bkthLUFsWjlScGw5Qy1fMUpWcm85cHZVblJlWkRLUHhaTno3WGttX3lsdjFydVd1SUN4LWxfX3JzRm9uZkk5eTRIYUtmeE5MVjBfbVhzTnRIOFNmZHBienFxaEFoNURv?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxNRWs1M25PVVAxTXl0U2ppUWJUb1JlVHRHVm5mU0N6bW9odHBKX0pDZS1IUWQ3ekFaa2VTVUdCTGw1YktwQ3U2M3ZqNDRRbE9NUmlRdUZXam93T1hFWmZQSWRpZUJHakJXZXZUUXI5dTJHMW9nTVdQR3ZodWo3VEY3QmptbXNaeWNxLXplcklkejI0TEVlMjdvV0N3?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "by_tier": {"direct": [{"title": "Oculis Holding AG (OCS) Investigation: Bronstein, Gewirtz & Gross", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Oculis Holding AG (NASDAQ: OCS) on behalf of investors. This investigation follows a significant stock price drop after Oculis announced the failure of its lead candidate, OCS-01, in two late-stage trial", "url": "https://natlawreview.com/press-releases/oculis-holding-ag-ocs-investigation-bronstein-gewirtz-grossman-llc-2", "source_name": "The National Law Review", "published_at": "2026-07-15T09:12:45", "published_display": "15 Jul 2026 09:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Oculis Holding AG \u2013 NASDAQ:OCSAW", "summary": "This article focuses on the enterprise value to revenue forward metric for Oculis Holding AG, traded on NASDAQ under the symbol OCSAW. It appears to be a financial data snippet from TradingView, providing an overview of the company's financial information within that platform. Th", "url": "https://www.tradingview.com/symbols/NASDAQ-OCSAW/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T19:10:41", "published_display": "13 Jul 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Oculis Holding AG \u2013 NASDAQ:OCSAW", "summary": "This article provides financial data for Oculis Holding AG (NASDAQ: OCSAW), specifically focusing on its Enterprise Value to EBITDA forward metric. The content highlights that the market was closed at the time of publication, with no trades observed. It appears to be a stub or da", "url": "https://www.tradingview.com/symbols/NASDAQ-OCSAW/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T09:41:16", "published_display": "13 Jul 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Technical Reactions to OCS Trends in Macro Strategies", "summary": "This article provides a technical analysis of Oculis Holding Ag (NYSE: OCS), highlighting weak near-term sentiment but strong mid and long-term support signals. It outlines institutional trading strategies including position trading, momentum breakout, and risk hedging, along wit", "url": "https://news.stocktradersdaily.com/news_release/101/Technical_Reactions_to_OCS_Trends_in_Macro_Strategies_071126070602_1783811162.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-11T19:06:00", "published_display": "11 Jul 2026 19:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities", "summary": "Oculis Holding AG announced the publication of notifications regarding transactions by persons discharging managerial responsibilities. Specifically, the notification concerns the vesting and settlement of Restricted Stock Units (RSUs) previously granted to a company director, Ri", "url": "https://uk.finance.yahoo.com/news/oculis-publishes-notifications-transactions-persons-200500440.html", "source_name": "Market source", "published_at": "2026-07-08T20:05:03", "published_display": "08 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Oculis Holding AG \u2013 SWB:CR5", "summary": "This page from TradingView provides financial information for Oculis Holding AG (SWB:CR5), specifically focusing on its price to book forward metric. The content highlights the company's financials, news, and community forecasts, and mentions that the market was closed with no tr", "url": "https://www.tradingview.com/symbols/SWB-CR5/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T02:10:45", "published_display": "08 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Oculis Holding AG \u2013 NASDAQ:OCS", "summary": "This article provides financial information for Oculis Holding AG (NASDAQ: OCS), specifically focusing on its forward price-to-earnings ratio. It presents a data table indicating the period, value, change, and percentage change for this metric, noting that the data is sourced fro", "url": "https://www.tradingview.com/symbols/NASDAQ-OCS/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T01:10:45", "published_display": "08 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Oculis Holding AG \u2013 SWB:CR5", "summary": "This article provides financial data for Oculis Holding AG (SWB:CR5) focusing on its enterprise value to revenue forward metric. The content indicates the stock is traded on the Stuttgart Stock Exchange and presents an overview of its financials within the TradingView platform. T", "url": "https://www.tradingview.com/symbols/SWB-CR5/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T14:09:53", "published_display": "07 Jul 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference", "summary": "Oculis Holding AG announced its participation in the Piper Sandler Virtual Ophthalmology Conference, where its management will discuss its late-stage pipeline. Key programs include Privosegtor for optic neuropathies, which has received Breakthrough Therapy and PRIME designations,", "url": "https://www.globenewswire.com/news-release/2026/07/02/3321128/0/en/oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-conference.html", "source_name": "GlobeNewswire", "published_at": "2026-07-06T20:41:16", "published_display": "06 Jul 2026 20:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis Holding AG Warrants 2023-06.03.28 on OCULIS HOLDING Financial Disclosures & SEC Filings", "summary": "This page provides access to financial disclosures and SEC filings for Oculis Holding AG (OCSAW). It lists various documents including earnings reports, annual reports, event transcripts from conferences, and significant press releases, spanning from 2025 to 2026. The disclosures", "url": "https://www.tradingview.com/symbols/NASDAQ-OCSAW/documents/", "source_name": "TradingView", "published_at": "2026-07-06T05:42:08", "published_display": "06 Jul 2026 05:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis to present updates on late-stage eye disease treatments at Piper Sandler conference", "summary": "Oculis Holding AG announced its participation in the Piper Sandler Virtual Ophthalmology Conference on July 10, 2026. The company will discuss its advanced portfolio of eye disease treatments, including Privosegtor and Licaminlimab. Oculis aims to achieve significant milestones i", "url": "https://pluang.com/en/news-feed/oculis-ikut-konferensi-virtual-piper-sandler-ophthalmology", "source_name": "Pluang", "published_at": "2026-07-02T08:40:46", "published_display": "02 Jul 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis to Participate in Piper Sandler Virtual Ophthalmology Conference Fireside Chat", "summary": "Oculis Holding AG will participate in a fireside chat at the Piper Sandler Virtual Ophthalmology Conference on July 10, 2026. The company will discuss its late-stage product pipeline, including Privosegtor, which has Breakthrough Therapy designation for optic neuritis, and Licami", "url": "https://www.quiverquant.com/news/Oculis+to+Participate+in+Piper+Sandler+Virtual+Ophthalmology+Conference+Fireside+Chat", "source_name": "Quiver Quantitative", "published_at": "2026-07-02T08:10:00", "published_display": "02 Jul 2026 08:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis to Present Late-Stage Pipeline Update at Piper Sandler Virtual Ophthalmology Conference", "summary": "Oculis Holding AG, a biopharmaceutical company, announced it will present a late-stage pipeline update at the Piper Sandler Virtual Ophthalmology Conference on July 10, 2026. The presentation will highlight Privosegtor, a neuroprotective candidate with Breakthrough Therapy design", "url": "https://www.quiverquant.com/news/Oculis+to+Present+Late-Stage+Pipeline+Update+at+Piper+Sandler+Virtual+Ophthalmology+Conference", "source_name": "Quiver Quantitative", "published_at": "2026-07-02T07:40:46", "published_display": "02 Jul 2026 07:40", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis spotlights late-stage eye drugs at Piper Sandler event", "summary": "Oculis (Nasdaq: OCS) is scheduled to participate in the Piper Sandler Virtual Ophthalmology Conference on July 10, 2026, where its management will discuss late-stage programs. These include Privosegtor, which has FDA Breakthrough Therapy and EMA PRIME designations for optic neuri", "url": "https://www.stocktitan.net/news/OCS/oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-ciy984j33vsr.html", "source_name": "Stock Titan", "published_at": "2026-07-02T07:40:46", "published_display": "02 Jul 2026 07:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trading the Move, Not the Narrative: (OCS) Edition", "summary": "This article provides an AI-driven analysis for Oculis Holding Ag (NYSE: OCS), highlighting strong sentiment across all horizons for an overweight bias despite elevated downside risk due to a lack of additional long-term support. It details three institutional trading strategies\u2014", "url": "https://news.stocktradersdaily.com/news_release/134/Trading_the_Move,_Not_the_Narrative:_OCS_Edition_063026055802_1782856682.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-30T17:58:00", "published_display": "30 Jun 2026 17:58", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis Holding AG Actuals & Estimates (NASDAQ:OCS)", "summary": "This article provides an overview of Oculis Holding AG (NASDAQ: OCS) stock, including its current price, market capitalization, and analyst forecasts. It details financial actuals and estimates for the income statement, balance sheet, and cash flow, along with frequently asked qu", "url": "https://www.tradingview.com/symbols/NASDAQ-OCS/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T02:09:37", "published_display": "26 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis (NASDAQ: OCS) details late-stage eye drugs and cash runway into 2029", "summary": "Oculis Holding AG (NASDAQ: OCS) has provided an updated corporate presentation detailing its late-stage ophthalmic and neuro-ophthalmic drug pipeline and a strong financial position, projecting a cash runway into the second half of 2029, excluding a CHF100 million loan facility. ", "url": "https://www.stocktitan.net/sec-filings/OCS/6-k-oculis-holding-ag-current-report-foreign-issuer-54e0573b556d.html", "source_name": "Stock Titan", "published_at": "2026-06-25T19:40:23", "published_display": "25 Jun 2026 19:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OCS Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "Oculis Holding AG (OCS) has a current stock price of $11.74, showing a 1.56% increase in the last 24 hours. Analysts provide a wide forecast range for OCS, with a maximum estimate of $51.93 and a minimum of $22.67. The company's stock has experienced significant volatility, inclu", "url": "https://www.tradingview.com/symbols/NASDAQ-OCS/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T17:40:23", "published_display": "25 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS", "summary": "Pomerantz LLP is investigating claims on behalf of investors of Oculis Holding AG (NASDAQ: OCS) due to potential securities fraud or unlawful business practices. This investigation stems from Oculis's announcement on May 29, 2026, that two late-stage trials for its lead candidate", "url": "https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-oculis-holding-ag---ocs-302808841.html", "source_name": "PR Newswire", "published_at": "2026-06-25T15:09:50", "published_display": "25 Jun 2026 15:09", "sentiment": "negative", "sentiment_pct": 28, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OCS - Oculis Holding AG Revenue Breakdown", "summary": "This article provides a detailed financial breakdown of Oculis Holding AG (OCS), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators, insider/institutional ownership, and analyst recommenda", "url": "https://finviz.com/stock?t=OCS&b=2&p=m&ty=rv", "source_name": "Finviz", "published_at": "2026-06-24T16:12:22", "published_display": "24 Jun 2026 16:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(OCS) Volatility Zones as Tactical Triggers", "summary": "This article from Stock Traders Daily discusses Oculis Holding Ag (NYSE: OCS), providing a detailed analysis based on AI-generated signals. It identifies a positive near-term sentiment within a long-term strength context, despite mid-term weakness and elevated downside risk. The ", "url": "https://news.stocktradersdaily.com/news_release/139/OCS_Volatility_Zones_as_Tactical_Triggers_061926044602_1781901962.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-19T17:09:45", "published_display": "19 Jun 2026 17:09", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm", "summary": "The Schall Law Firm is investigating Oculis Holding AG (NASDAQ: OCS) for potential securities law violations after the company announced its Phase 3 DIAMOND trials failed to meet primary endpoints, leading to a decision against pursuing FDA filing for its drug candidate. Investor", "url": "https://www.globenewswire.com/news-release/2026/06/17/3313555/0/en/ocs-investors-have-opportunity-to-join-oculis-holding-ag-fraud-investigation-with-the-schall-law-firm.html", "source_name": "GlobeNewswire", "published_at": "2026-06-17T14:10:33", "published_display": "17 Jun 2026 14:10", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Oculis Holding AG (OCS) And Encourages Shareholders to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating Oculis Holding AG (OCS) following the failure of its lead candidate, OCS-01, in two late-stage trials for diabetic macular edema. This news led to a significant drop in Oculis's stock price. The firm is encouraging affected shar", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-is-investigating-oculis-holdi-1172660", "source_name": "ACCESS Newswire", "published_at": "2026-06-17T10:39:10", "published_display": "17 Jun 2026 10:39", "sentiment": "negative", "sentiment_pct": 20, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis executive Sylvia Cheung reports June 10 share purchase", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNWWUxbXZIRFVLS1MyZUxpak9JMmVRTkpENEZmUm1tV0ltVXBoY011RE9adnZlWWliQzctdGVPanpxeG1xclVSZ2xwZG1qZWFUb25UUEFCZDVRXzRPaTFSV0Iwcks1WUczMWNoYXQxZ25yanJRalFSNmhMUTdQYnlFVFQ4RlVzM2VWYlRSWnZoN1ZVR1h1c19uZmU1Y1NzR1RSS0ZXOV9FeFotMjFPTGwtcg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/oculis-present-privosegtor-upcoming-clinical-080000630.html", "source_name": "GlobeNewswire", "published_at": "2026-06-11T08:00:00+00:00", "published_display": "11 Jun 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/oculis-announces-first-patient-randomized-080000550.html", "source_name": "GlobeNewswire", "published_at": "2026-06-09T08:00:00+00:00", "published_display": "09 Jun 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis executive and board member buys more company shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPMmtHYm5CbkRFYWdPV1h1UENJQ2ZnYUpaem5ubDNFbW1SZFpTaXI4UC1ORHV2UkNhaUViSDA4czhOTm9JZjhISGdBVUgxQ3hzRUJ6Si1jN09uc3JpbUdyR1ZXRERKcmdXTm9IclB0MmFSQzlrZHNYZ1B1cTVmVVpDWFoxc2w1WjNma0dEX2tfTGpOcXJ3alBocEdFTk15dTcwby1VRnNnN2tzMUljVHM2aA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/oculis-present-47th-annual-goldman-192500295.html", "source_name": "GlobeNewswire", "published_at": "2026-06-08T19:25:00+00:00", "published_display": "08 Jun 2026 19:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles", "summary": "", "url": "https://finance.yahoo.com/m/d56fa666-fe35-3c9c-a633-59b92a9d0d77/nan-fung-group-sells-%244.3.html", "source_name": "Motley Fool", "published_at": "2026-06-08T11:16:03+00:00", "published_display": "08 Jun 2026 11:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eye drug maker Oculis to outline $7B+ optic neuritis market plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOZDZwYWF1c2l0YTVCNEc4UklaMTFlS3pMb0UtclQxYzVMQzdydlNxcVpnZGxFRmw2NW5lc3htaVBqRlU2OHluWWt6b1dKOC1aN3RYanIzNmNUV3BlaGJMcWphRXFLUDZqOHVhdGF1OHRGdnZzWTJBdWl1M29VWGZBZF8zbE40Q21jY2hPVFRvVTc2TTFseFY5dmFQRENMM194S0pFenVFSlhPN2xDak1fS1lfb0FrYXlqSFFrYkhMcw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis Holding AG (OCS) Securities Fraud Investigation - Levi & Korsinsky", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxOUGtwdWtFdkRaN1VvcFFkNzI0THhxdEtqckd4cjBjVHBnUGQzcHVZVlY2dlBweU0yaWpjeGUtVVFuVUF3bVpia3V1MmhWS0U3UVNVVDdUaUo0VjQzYUJSTTg3YkkyTkhOTF92RHBtb0xnd2pqNVcwN0VIRWsyZndpaEZsNldHV2ZJNEUtY3FiU3pJbV8wXzBjS0NfY09lUi1Qc2xybmkwM2NZeVNoRDQwZUsxeVlUVkdrS3JSSC1DRkxlUGFXXzFJ?oc=5", "source_name": "Morningstar", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lost Money on Oculis Holding AG (OCS)? Contact Levi & Korsinsky About Investigation", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPUld2dkhwQVg4WTQzV0t6MUcxZGc2TmVvTWdwTVBvaWQ0RnVwaVhMTGw1b3E1YlpMMFVlMmlFOGhwXzlmR1dVQVN3VkFXVEVjNjJkLVRMczBUZlpUaFpyWWQ1WWwtNGdqemEzQUFXTWVYTnR0eXdwNFgzSHd6R3dtUUJnYWV3VGdXVGoxYkM4aURiZlkwWU1OaUV4aE5uZXRuSTNDYWZqYkl5RVFodXRaX1lWRzdjbGZ6dENiMml4OA?oc=5", "source_name": "TMX Newsfile", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis Holding (OCS) Is Down 60.1% After OCS-01 Trial Failure And Pipeline Pivot \u2013 Has The Bull Case Changed?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OCS Stock Price and Chart \u2014 NASDAQ:OCS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTE5EZ1h6UmxTWEhMX19IMXlHcE1fN1BFSm81cncwR25HMnVodExBenhHbjNObkR0bHROQlRyZDNJalNLeDVLZWE3N1dJOGFaeEFrbjZWVlduXzFkNzQ?oc=5", "source_name": "TradingView", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Levi & Korsinsky Announces Investigation of Securities Claims Against Oculis Holding AG (OCS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxQV3dkTU1zM0ktNEpOVDl6LWFjcUc2Tnp2VXhpa2VodkxFeDR1RHM0emlxRW5VRm9HQUVMUnpDMEZFMW9UY0Utall1cXZfTlgzTGY5SmNuLTNaYnNOaG1neFRpYnlJOXNPXzRkUm1WUHg2RXgtQ0NfWmxjeUt2Q0NPTWJjN21IVDhpYlF3N3QyS2Jib3M5ZmIydXpUb29tU2FHSjRMb3hxMF9FamNKRktJeWVxcmNmbGpTVklVTkMweWNVUW55LWdfVnE2MWJzMTY5WlBVWm90alo1T0tUVzh6blRjY3pqOE5mSS12NGdiYmhyVWdORVFv?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OCS Investor Alert: Levi & Korsinsky Investigates Oculis Holding AG (OCS) for Potential Securities Fraud", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxQOVR6T3hPbGJNWlBGOFVHc0RKbXcwcEk4TGtjT09iUEY4TnROWkhIWUktUllxaS1iZzZhZTNpck1vMTVvaVpQY3p0VExmeU5JZDdSM3RXbnhTMnpHWGZvaXEyWWJUMlctM3VfYjh0bmlKcWc0SXdJS0RqbDdzTGh1RjBtM0NBZWVKeGM2RzlFazJfNXlLUTRiQ21rV2RpT2tuT1o2TFI1UjV0blVJQ0JiNENyeWFZa2xVSThJY3hZeUhKWmdyZThnaHhSMVpOa2xEVkRTSGNqX1dWcXV1S2hQTlRKcWEtc3FFVzFjYQ?oc=5", "source_name": "Business Wire", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis Resets After OCS-01 Setback And Refocuses On Late-Stage Pipeline", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Fair Value analysis helped investors avoid a 42% loss in Oculis By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPRm5ua0JKQWRzV2gwOVlPcm9sdGF5NHRmb2NWTmhVNDh0RXJDTnozZjZPdGliZWdaZlZuWlRPczlOTWJkd2wyLTBnczM2emlsMkMzUmhPSHFHYWZaZHpoY0xkYWRnZGtrU1ZUbjIyc3FZaHVQdWRHR2JxamFhWng1dnh6RHRuU0JjYzdFSFAyM0xxM3J3Mkc4X3FqeEdnS0R3b3NfVFVQaHlqU2Vpam5XcmJ5LVdtNlZ6UnlxNXJJbUZGSGlLQkE?oc=5", "source_name": "Investing.com", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis Holding AG Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Oculis Holding AG (OCS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigJBVV95cUxQYURKUUR4X3B2bDdMeGdUM2RHRXk2YjVHTmcxTDBXT1A0TGlUUGFLckNhR29XbUVlajFjN3oyMThiZzBBcWlZMmJuZllCeXlSNWp5WlotV1FpYlg1ZDJyclBIZXJDU0NXVVZZMEtzMmZNTUtNbGhsUm93SUl6NXkwWjFpcjVRMHhsV3N5czJGNXNTeURjTmwzXzdKWnVtQS11ek1IcmowT2Jtd0RFWU5wSEFmcTNmUzF3NEl0MldnNExfamNtWWtjSkNVSl9RQ1A3dnkxVlFCZlVaZ2pXVjRxamtNbGM5Z1NjdTR2cTJ4Z1BnREgyNGtvN0VweGljVnFfTGVNSWU4M1RIQQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis Shelves FDA Filing After Phase 3 DME Trials Miss Key Vision Goals", "summary": "", "url": "https://finance.yahoo.com/m/8c0e74c5-50f6-333d-b4df-f3ab03dec3a6/oculis-shelves-fda-filing.html", "source_name": "MarketBeat", "published_at": "2026-05-31T21:03:56+00:00", "published_display": "31 May 2026 21:03", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis Holding AG Phase 3 Trial of Potential Eye Drops for Diabetic Patients Fails to Primary Endpoint", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/oculis-holding-ag-phase-3-194641190.html", "source_name": "MT Newswires", "published_at": "2026-05-29T19:46:41+00:00", "published_display": "29 May 2026 19:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis Announces Phase 3 Trial Results for OCS-01 Eye Drops in Diabetic Macular Edema, Shifts Focus to Other Development Programs", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxPc1JkRDhQdE0xVi10LV85VjBRRnFodndtc05aQXQ3clRvVUxmTk5uRGhzcjctYUl3V2ptVldyaE83RVVVR3hRVWxyY2o2NXF2Mmw3SkF4R0ZNTExPaFYzeTJ2cTZOeHM3SDJLU3dzRjlFR2RyWWtSS01GVi13V1dKcTEwdFlqd2cwS0ViSzc0dE8zRW11NTlRRVh6N2h4R0RUaVo5UUdpdVRQOVpscnBtRnFSaXRqck1NbzNIMFJmVTdVMlBtLVN1QS00cHJIRWxPTGtCT0RORUFQdnRhMUxOZ2VtLTlkdWliTl9ON1U5WHYzX0FVSEM4?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Weighing Oculis Holding (NasdaqGM:OCS) Rich P/B Against DCF Upside After Strong Multi Year Share Gains", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOUlF3eVNTMl9qRV9lZDdnb21PeDVYRWJJNF9jM056RTBicGIzcEE1OU54RWk5cm9EMmR0OGNIY1A2UHB5bkthLUFsWjlScGw5Qy1fMUpWcm85cHZVblJlWkRLUHhaTno3WGttX3lsdjFydVd1SUN4LWxfX3JzRm9uZkk5eTRIYUtmeE5MVjBfbVhzTnRIOFNmZHBienFxaEFoNURv?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxNRWs1M25PVVAxTXl0U2ppUWJUb1JlVHRHVm5mU0N6bW9odHBKX0pDZS1IUWQ3ekFaa2VTVUdCTGw1YktwQ3U2M3ZqNDRRbE9NUmlRdUZXam93T1hFWmZQSWRpZUJHakJXZXZUUXI5dTJHMW9nTVdQR3ZodWo3VEY3QmptbXNaeWNxLXplcklkejI0TEVlMjdvV0N3?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 86, "total_relevant": 53, "sentiment_summary": {"positive": 9, "negative": 11, "neutral": 33, "score": 50, "total": 53, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 14.3, "count": 26}, {"event": "earnings", "label": "Earnings", "weight": 7.56, "count": 16}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 4.75, "count": 8}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 9, "negative_events": 11}, "market_context": {"has_market_context": true, "latest_close": 13.63, "latest_week": "2026-07-10", "one_week_move": -3.5, "four_week_move": 22.9, "twelve_week_move": -50.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.311015, "market_dynamics_buy_signal": false, "relative_strength": -45.883067, "fair_value_gap": -18.3, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 54.9618, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-3.5% over one week, +22.9% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 57, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 10}, {"label": "Market source", "count": 9}, {"label": "GlobeNewswire", "count": 6}, {"label": "Stock Titan", "count": 5}, {"label": "simplywall.st", "count": 4}, {"label": "Stock Traders Daily", "count": 3}, {"label": "Quiver Quantitative", "count": 3}, {"label": "PR Newswire", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 44}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 26}, {"label": "Earnings", "count": 16}, {"label": "Regulatory and legal", "count": 8}, {"label": "Analyst action", "count": 1}, {"label": "Balance sheet", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "44", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-3.5% over one week, +22.9% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Oculis Holding AG (OCS) Investigation: Bronstein, Gewirtz & Gross"}], "updated_at": "2026-07-17T16:59:32.138073+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}